Peptide research guide
A guide to the peptide and bioregulator records in Molekul’s Soviet and Russian pharmacology collection.
Explore individual preparations, original-language publications and research settings. Similar names or classifications do not establish equivalent composition, effects or safety.
Pinealon, Semax and Epitalon research guides
Pinealon (EDR) peptide research ↗
Human evidence, sleep and REM, neuronal aging, and safety.
Pinealon is the EDR tripeptide studied in neuronal models and limited human reports. Its best-known sleep claims go beyond the clinical evidence currently available in this collection.
Semax peptide research ↗
Clinical studies, cognition, BDNF mechanisms, and safety.
Semax is an ACTH-fragment-derived peptide investigated in stroke, neurological conditions and experimental brain models. Clinical reports and brain-imaging changes answer different questions from memory enhancement in healthy people.
Epitalon (Epithalon) peptide research ↗
Telomeres, human melatonin studies, longevity, and safety.
Epitalon, also spelled Epithalon, is the synthetic AEDG tetrapeptide. Human hormone studies and cell-level telomere findings are relevant research leads, but they do not establish human lifespan extension.
Tissue extracts, defined peptides and cyclic candidates.
The expanded collection follows historical marrow and thymus preparations, newer synthetic candidates and tissue-product reports. Shared tissue targets do not establish identical molecules or a continuous development lineage.
| Branch | Preparations | What remains unresolved |
|---|---|---|
| Historical tissue mixtures | Haemalin, Thymalin, Thymohaemin, Vilosen, Vasonin, Tactivin | Exact composition, formulation continuity, clinical allocation and original archival methods. |
| Defined small peptides | Thymogen, Stemokin / Neogen, Thymodepressin, Thymohexin, EDL | Sequence, stereochemistry and bond position matter. Opposite assay responses do not establish a common receptor. |
| Cyclic candidates | CP-88, AWE18 and numbered experimental analogues | Oral activity in animals is not measured human bioavailability. CD34 changes and colonies do not prove long-term stem-cell regeneration. |
| Named tissue products | Gotratix, Cerluten, Endoluten, Svetinorm and related preparations | Institutional reports, commercial reproductions and independent journal studies must remain distinguishable. |
Additional preparation records
Haemalin ↗
Research profile with linked sources
Historical bone-marrow peptide mixture; distinct from modern Bonomarlot.
Thymohaemin ↗
Research profile with linked sources
Historical combined thymus and bone-marrow preparation studied alongside Thymalin and Haemalin.
Thymohexin ↗
Research profile with linked sources
Synthetic hexapeptide investigated in radiation-related hematopoietic models. Original sequence verification is needed because Asp and Asn renderings conflict.
Vasonin ↗
Research profile with linked sources
Historical vascular-wall polypeptide research lead. Exact preparation and its relationship to Vasolin require original-source verification.
Vilosen ↗
Research profile with linked sources
Animal-thymus nonprotein extract reported in asthma, hepatitis and immune research. Historical clinical reports include combinations with Splenin; it is distinct from synthetic Vilon.
Tactivin ↗
Research profile with linked sources
Thymus-derived polypeptide preparation studied as an immune adjunct and in animal learning models. Clinical findings include a reported infection reduction in leukemia and a neutral melanoma comparison.
Thymodepressin ↗
Research profile with linked sources
Synthetic γ-D-Glu-D-Trp immunosuppressive dipeptide. Russian reports cover psoriasis, autoimmune cytopenias and myositis; a rheumatoid arthritis trial registration has no verified results.
Stemokin / Neogen ↗
Research profile with linked sources
Synthetic Ile–Glu–Trp tripeptide (IEW), studied in hematopoietic experiments and Russian clinical immune research. It is distinct from whole tissue extracts.
CP-88 ↗
Research profile with linked sources
Experimental cyclic peptidomimetic cyclo-{E(I)-E(W)}Na studied in mouse and laboratory hematopoietic assays. Human efficacy and safety are not established here.
AWE18 ↗
Research profile with linked sources
Experimental cyclic Ala/Glu/Trp peptidomimetic discussed in the development literature. Its evidence must remain separate from CP-88.
EDL ↗
Research profile with linked sources
Glu–Asp–Leu tripeptide studied in renal-cell aging models. It is distinct from AED/Cartalax.
Osteogenic growth peptide ↗
Research profile with linked sources
An international peptide-research comparator with original osteoblast and rodent studies. Full-length OGP, its active fragment and marrow extracts are distinct research preparations.
Gotratix ↗
Research profile with linked sources
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Sigumir ↗
Research profile with linked sources
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Taxorest ↗
Research profile with linked sources
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Chelohart ↗
Research profile with linked sources
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Suprefort ↗
Research profile with linked sources
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Ventfort ↗
Research profile with linked sources
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Endoluten ↗
Research profile with linked sources
Pineal-derived low-molecular-weight peptide mixture named in the original 113-worker Gazprom program. The paper reports program-level sick leave, without an Endoluten-specific effect.
Svetinorm ↗
Research profile with linked sources
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Cerluten ↗
Research profile with linked sources
Brain-associated tissue-peptide preparation named in risk-based assignments in the 113-worker Gazprom program and in institute reports. Shared program findings do not isolate Cerluten.
Vladonix ↗
Research profile with linked sources
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Visoluten ↗
Research profile with linked sources
A named tissue-derived preparation with an institute-attributed clinical report reproduced in a commercial brochure. Reported findings and provenance limits are separated below.
Pielotax ↗
Research profile with linked sources
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Glandokort ↗
Research profile with linked sources
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Bonomarlot ↗
Research profile with linked sources
Animal bone-marrow peptide mixture described in an institute anemia report. It is distinct from synthetic Stemokin and from historical Haemalin.
Bonothyrk ↗
Research profile with linked sources
A named tissue-derived preparation with an institute-attributed clinical report reproduced in a commercial brochure. Reported findings and provenance limits are separated below.
Stamakort ↗
Research profile with linked sources
A named tissue-derived preparation with an institute-attributed clinical report reproduced in a commercial brochure. Reported findings and provenance limits are separated below.
Chitomur ↗
Research profile with linked sources
A named tissue-preparation research lead associated with urinary bladder. Original report and marketed formulation require separate verification; no equivalence to a single synthetic peptide is assumed.
Testoluten ↗
Research profile with linked sources
A named tissue-derived preparation with an institute-attributed clinical report reproduced in a commercial brochure. Reported findings and provenance limits are separated below.
Zhenoluten ↗
Research profile with linked sources
A named tissue-derived preparation with an institute-attributed clinical report reproduced in a commercial brochure. Reported findings and provenance limits are separated below.
Tireogen ↗
Research profile with linked sources
A named tissue-derived preparation with an institute-attributed clinical report reproduced in a commercial brochure. Reported findings and provenance limits are separated below.
Libidon ↗
Research profile with linked sources
A prostate-derived peptide mixture described in a Russian institute-report reproduction. It is a distinct preparation from Prostatilen and the synthetic peptide Prostamax.
Publications added to the archive
These are publication records, not a count of independent trials. Reprints, translations, reviews and potentially overlapping cohorts are not independent replications.
- 1992: Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity.
- 2022: Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2.
- 1996: Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.
- 2005: Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.
- 2020: Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides.
- 2016: Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.
- 2014: [Tripeptides slow down aging process in renal cell culture].
- 2009: The effects of the EW--peptide optical and chemical isomers on the hemopoietic stem cells in intact and irradiated mice.
- 2007: Thymodepressin inhibits migration of CD34+ cells from bone marrow in normal and granulocyte CSF-stimulated hemopoiesis.
- 2007: The effects of the EW dipeptide optical and chemical isomers on the CFU-S population in intact and irradiated mice.
- 2006: Effects of structural and "mixed" isomers of Glu-Trp dipeptide on normal hemopoietic stem cells.
- 2005: [Thymodepressin protects murine bone marrow CFU-S from the hyperthermic damage].
- 2003: [Immunogenic peptide neogen stimulates postradiation recovery thrombopoiesis].
- 2001: Synthetic peptide thymodepressin promoted take of transplanted hemopoietic precursor cells in the bone marrow of irradiated mice.
- 2000: [The synthetic peptide D-(iEW) (thymodepressin) protects bone marrow CFU-S from ionizing radiation exposure].
- 1997: Studies of the mechanism of the anticonvulsant effect of delta-sleep-inducing peptide in conditions of increased oxygen tension.
- 1994: [Radiation protective effect of low molecular weight thymus preparations].
- 1993: [Radioprotective effect of synthetic immunomodulators on hemopoietic CFU-S].
- 1993: [A cytomorphological basis for the correction of radiation-induced immunodeficiencies and hematopoietic depression using thymus and bone marrow peptides].
- 1992: [The effect of the synthetic immunomodulator thymogen on radiation-induced carcinogenesis in rats].
- 1991: [Correction with thymic and bone marrow peptides of radiation injuries of immuno- and hemopoiesis].
- 1991: [The correction of secondary radiation-induced immunodeficiencies].
- 1989: [The cytomorphological characteristics of hemopoiesis and of the organs of immunogenesis in exposure to thymus and bone marrow peptides during hematopoietic depression].
- 1984: [Effect of polypeptides isolated from the bone marrow on immunity and hemostasis].
- 2024: Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation
- 2023: Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
- 2015: Stemokin in treatment and prevention of pyoderma in military personnel
- 2011: Bonomarlot: institute clinical report
Open questions and sources to locate
Tissue-preparation clinical reports
Gotratix, Sigumir, Taxorest, Chelohart, Suprefort, Ventfort, Endoluten, Svetinorm, Cerluten, Vladonix, Visoluten, Pielotax, Glandokort and Bonomarlot
Recover the complete 2011 report collection and verify preparation, allocation and tables. Commercial mirrors are copies, not independent trials. Gotratix sample counts conflict; Cerluten EEG subsets and attention measures require separate denominators; Endoluten hormone changes do not establish cancer treatment. Svetinorm within-group changes must not be presented as between-group benefits. Bonomarlot is an adjunctive iron-treatment report, not marrow regeneration.
Source details ↗Stemokin clinical source lineage
2011 Kakhishvili dissertation → 2015 conference report
Recover Chapter 5, randomization and blinding details, participant overlap, immune-marker tables and occupational-stress measures. Cortisol changes alongside infection treatment cannot establish a direct hormonal effect or improved performance. Locate the 2007, 2010 and 2011 related publications before adding independent-study counts.
Source details ↗Cyclic platform and patent families
IsoNeogen; A1–A5; B1/B5/B6/B9; E1/E3
These are unresolved family/designation leads, not verified synonyms for the numbered 2016 compounds 3–7. Match chemical structures and experimental endpoints before creating individual compound identities. Patent claims are not clinical results.
Source details ↗Neogen vaccine-adjuvant branch
Neogen / modified-linkage candidates
Separate mouse antibody and human-cell experiments from clinical vaccination outcomes. A strong vaccine-only response and timing-dependent effects complicate interpretation.
Source details ↗DSIP archival expansion
Sametsky 1996; Lysenko 1993; adaptation monographs; ID1/ID3/ID8
Acquire original dissertations and books before transferring results to ordinary DSIP. Hyperoxia is distinct from hypoxia. Age-dependent analogue effects, thermoregulation and combination studies require preparation-specific records.
Source details ↗Additional catalogue identities
Ensil, Panaxod, Reviplant, Tireogen, Libidon, Bonothyrk, Stamakort, Chitomur, Testoluten and Zhenoluten
Names alone do not establish peptide composition, tissue origin, regulatory status or efficacy. Catalogue leads remain explicitly unresolved; non-peptide products must not be classified by association.
Existing bioregulator evidence
Pancragen, Retinalamin, Epitalon, Cartalax, Thymalin and Vilon
Retain existing primary records and check formulation, cohort overlap and neutral endpoints. Pancragen KEDW and amidated formulations need source-level distinction. Retinalamin active-route comparisons are not untreated controls; extract outcomes do not transfer to defined peptides.
Older peptide programs
Vasonin, Vilosen, Tactivin, Thymohexin and OGP
Recover original vascular/coagulation, thymic and marrow studies. Avoid assuming a molecular lineage from a shared tissue target. Thymohexin sequence ambiguity remains open; OGP is a separate international comparator.
Explore peptide research profiles
Cortexin ↗
Кортексин · Research profile with linked sources
Semax ↗
Семакс · Research profile with linked sources
Pinealon ↗
Пинеалон · Research profile with linked sources
Epitalon ↗
Эпиталон · Research profile with linked sources
Thymalin ↗
Тималин · Research profile with linked sources
Vilon ↗
Вилон · Research profile with linked sources
Vesugen ↗
Везуген · Research profile with linked sources
Selank ↗
Селанк · Research profile with linked sources
Thymogen ↗
Тимоген · Research profile with linked sources
Normophthal ↗
Нормофтал · Research profile with linked sources
Cartalax ↗
Карталакс · Research profile with linked sources
Chonluten ↗
Хонлутен · Research profile with linked sources
Prostamax ↗
Простамакс · Research profile with linked sources
Livagen ↗
Ливаген · Research profile with linked sources
Cortagen ↗
Кортаген · Research profile with linked sources
Pancragen ↗
Панкраген · Research profile with linked sources
Cardiogen ↗
Кардиоген · Research profile with linked sources
Testagen ↗
Тестаген · Research profile with linked sources
Bronchogen ↗
Бронхоген · Research profile with linked sources
Cerebrolysin ↗
Церебролизин · Research profile with linked sources
KED ↗
Пептид KED · Research profile with linked sources
PCC ↗
Полипептидный комплекс хрящевой ткани · Research profile with linked sources
Epithalamin ↗
Эпиталамин · Research profile with linked sources
Vasolin / Slavinorm ↗
Вазолин / Славинорм · Research profile with linked sources
Ventvil ↗
Вентвил · Research profile with linked sources
Prostatilen ↗
Простатилен · Research profile with linked sources
Retinalamin ↗
Ретиналамин · Research profile with linked sources
Ovagen ↗
Оваген · Research profile with linked sources
Crystagen ↗
Кристаген · Research profile with linked sources
DSIP ↗
Дельта-сон-индуцирующий пептид · Research profile with linked sources
Haemalin ↗
Гемалин · Research profile with linked sources
Thymohaemin ↗
Тимогемин · Research profile with linked sources
Thymohexin ↗
Тимогексин · Research profile with linked sources
Vasonin ↗
Вазонин · Research profile with linked sources
Vilosen ↗
Вилозен · Research profile with linked sources
Tactivin ↗
Тактивин · Research profile with linked sources
Thymodepressin ↗
Тимодепрессин · Research profile with linked sources
Stemokin / Neogen ↗
Стемокин / Неоген · Research profile with linked sources
CP-88 ↗
Пептидомиметик CP-88 · Research profile with linked sources
AWE18 ↗
Пептидомиметик AWE18 · Research profile with linked sources
EDL ↗
Пептид EDL · Research profile with linked sources
Osteogenic growth peptide ↗
Остеогенный ростовой пептид · Research profile with linked sources
Gotratix ↗
Готратикс · Research profile with linked sources
Sigumir ↗
Сигумир · Research profile with linked sources
Taxorest ↗
Таксорест · Research profile with linked sources
Chelohart ↗
Челохарт · Research profile with linked sources
Suprefort ↗
Супрефорт · Research profile with linked sources
Ventfort ↗
Вентфорт · Research profile with linked sources
Endoluten ↗
Эндолутен · Research profile with linked sources
Svetinorm ↗
Светинорм · Research profile with linked sources
Cerluten ↗
Церлутен · Research profile with linked sources
Vladonix ↗
Владоникс · Research profile with linked sources
Visoluten ↗
Визолутен · Research profile with linked sources
Pielotax ↗
Пиелотакс · Research profile with linked sources
Glandokort ↗
Гландокорт · Research profile with linked sources
Bonomarlot ↗
Бономарлот · Research profile with linked sources
Bonothyrk ↗
Бонотирк · Research profile with linked sources
Stamakort ↗
Стамакорт · Research profile with linked sources
Chitomur ↗
Читомур · Research profile with linked sources
Testoluten ↗
Тестолутен · Research profile with linked sources
Zhenoluten ↗
Женолутен · Research profile with linked sources
Tireogen ↗
Тиреоген · Research profile with linked sources
Libidon ↗
Либидон · Research profile with linked sources
GHK-Cu & GHK family ↗
GHK и структурные аналоги · Research profile with linked sources
Ms13-1 ↗
Пептид Ms13-1 · Research profile with linked sources
HCIQ2c1 ↗
Пептид HCIQ2c1 · Research profile with linked sources
M2IP ↗
Пептид M2IP · Research profile with linked sources
Nephropept ↗
Нефропепт · Research profile with linked sources
Prostateks ↗
Простатекс · Research profile with linked sources
Pineamin ↗
Пинеамин · Research profile with linked sources
NGF mimetics: GK & GTS series ↗
Миметики ФРН · Research profile with linked sources
BDNF mimetics: GSB, GBK & GTS ↗
Миметики BDNF · Research profile with linked sources
NT-3 mimetics: GTS-301 & GTS-302 ↗
ГТС-301 / ГТС-302 · Research profile with linked sources
GZS-411 ↗
ГЗС-411 · Research profile with linked sources
CPG & GZK-111 ↗
ЦПГ / ГЗК-111 · Research profile with linked sources
Glyprolins & PGP hybrids ↗
Глипролины · Research profile with linked sources
Myelopid & MP-1–MP-6 ↗
Миелопид / миелопептиды · Research profile with linked sources
GB-115 & CCK analogues ↗
ГБ-115 · Research profile with linked sources
Liberol / TRH research ↗
Либерол · Research profile with linked sources
Bestim ↗
Бестим · Research profile with linked sources
Imunofan ↗
Имунофан · Research profile with linked sources
Gepon & ezrin-derived peptides ↗
Гепон · Research profile with linked sources
APHC peptide family ↗
Пептиды APHC · Research profile with linked sources
Hcr ASIC peptide family ↗
Пептиды Hcr · Research profile with linked sources
Ueq 12-1 ↗
Пептид Ueq 12-1 · Research profile with linked sources
PPK-V & brain peptide complexes ↗
ППК «В» и экспериментальные полипептидные комплексы мозга · Research profile with linked sources
Xemys ↗
Ксемис · Research profile with linked sources
HAEE ↗
Пептид HAEE · Research profile with linked sources
HAEEPGP ↗
Пептид HAEEPGP · Research profile with linked sources
Rumalon ↗
Румалон · Research profile with linked sources
How to read this research
Check whether a source describes humans, animals, cells, or a review of earlier work. Then examine the population, comparison, measured outcomes, and access to the complete methods. An English abstract can help locate a paper but cannot replace its full report.
Human research in a particular clinical condition does not establish benefit for healthy people or for other conditions. The personal sleep diary is a separate observational record, not clinical evidence for a peptide.
Research archive ↗
Study populations, methods and source limitations.
Bibliography & PDFs ↗
Available sources and documents still needed.